Knight Therapeutics Inc (TSE:GUD) had its target price lifted by research analysts at Scotiabank from C$10.50 to C$11.00 in a research note issued to investors on Friday. The firm presently has an “outperform” rating on the stock. Scotiabank’s target price indicates a potential upside of 8.91% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. CIBC decreased their target price on shares of Knight Therapeutics from C$13.00 to C$9.80 in a research note on Friday, January 13th. National Bank Financial raised their target price on shares of Knight Therapeutics from C$11.00 to C$11.75 in a research note on Wednesday, March 15th. TD Securities restated a “buy” rating and set a C$12.50 target price on shares of Knight Therapeutics in a research note on Tuesday, March 14th. Finally, Mackie cut shares of Knight Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from C$12.00 to C$10.75 in a research note on Wednesday, January 4th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of C$11.16.
Shares of Knight Therapeutics (TSE:GUD) opened at 10.10 on Friday. The company has a market capitalization of $1.34 billion and a price-to-earnings ratio of 71.13. Knight Therapeutics has a one year low of $7.20 and a one year high of $11.03. The stock has a 50 day moving average of $10.56 and a 200-day moving average of $9.93.
Your IP Address:
About Knight Therapeutics
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.